Targeting multiple oncogenes simultaneously improves response to therapy and circumvents acquired resistance to single target tyrosine kinase inhibitors

Autor: Gurå Therese Bergkvist, Mark Edmund Gray, Monoar Pallab, Seungmee Lee, Maybelle Qian Ting Loh, David Argyle, Donald Yool

Publikováno v: Bergkvist, G, Gray, M E, Pallab, M, Lee, S, Loh, M Q T, Argyle, D & Yool, D 2014, ' Targeting multiple oncogenes simultaneously improves response to therapy and circumvents acquired resistance to single target tyrosine kinase inhibitors ' European Society for Veterinary Oncology, Vienna, Austria, 22/05/14-24/05/14, pp. 86 .
University of Edinburgh-PURE

IntroductionEpidermal growth factor receptors 1 and 2 (EGFR, ErbB2), and cytosolic Src (c Src) are tyrosine kinases that stimulate cell survival, proliferation and migration and if dysregulated can act as oncogenes. Several tyrosine kinase inhibitors

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::2435e4e016f5cb22c3d087cf40d2b0aa
https://hdl.handle.net/20.500.11820/8e46785f-5ade-4da0-99be-3c8a1cb693b4